Although immune checkpoint inhibitors are treated more than?? There are encouraging results in tumors, but some patients have developed drug resistance and the efficacy of immunocheckpoint inhibitors needs to be further improved, so the development of the next generation of anti-tumor immuno-specific antibodies is of great value, and CD47 is one of the most promising targets in cancer immunotherapy.
Biopharmaceuticalcompany Innoventannounc today announced that the Phase I clinical trial (CIBI32A101) of recombinant anti-CD47/PD-L1 bispecific antibodies (IBI322) has officially begun and the first patients in China have entered the group.
CIBI322A101 is a Phase Ia/Ib clinical study conducted in China whose primary purpose was to assess the safety, tolerance and anti-tumor efficacy of IBI322 in patients with advanced malignancies with standard treatment failures.
IBI322 is a recombinant anti-CD47 / PD-L1 bispecific antibody that blocks the PD-1 / PD-L1 and CD47 /SIRP-alpha pathways.
preclinical studies show that IBI322 can effectively block CD47-SIRP-alpha interactions and induce macrophages to devour CD47-positive tumor cells.
on the other hand, IBI322 effectively blocks the binding of PD-1 to PD-L1 and activates CD4-positive T lymphocytes.